Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12790881 | 0.76 | PTGS2 (0.42) | MEN1KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL3666080 | 0.71 | ALDH1A1 (0.46) | MEN1KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL21661959 | 0.69 | AR (0.40) | RAB9ANTSR1GPR55ALDH1A1LMNA | |
| SCHEMBL13760654 | 0.68 | MAPT (0.44) | MEN1KMT2APLA2G1BATG4BRAB9A | |
| SCHEMBL6518530 | 0.68 | PTGS1 (0.51) | MEN1KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL3982046 | 0.67 | ALDH1A1 (0.46) | MEN1KMT2ARAB9AALDH1A1NPSR1 | |
| SCHEMBL21661958 | 0.66 | LMNA (0.41) | MEN1KMT2ARAB9ANTSR1GPR55 | |
| SCHEMBL29193615 | 0.66 | ALOX5 (0.39) | MEN1KMT2APLA2G1BATG4BALDH1A1 | |
| SCHEMBL1554147 | 0.64 | DDR2 (0.57) | MEN1KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL3064394 | 0.64 | CYP2A6 (0.43) | MEN1KMT2APLA2G1BATG4BRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052805-A1 | METHOD AND SYSTEM FOR DEPOSITING A METAL OR METALLOID ON CARBON NANOTUBES | ARKEMA FRANCE (FR) | 2011-03-03 | — | — | US | claimed |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-2240461-A1 | SUBSTITUTED FURANS AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009097991-A1 | SUBSTITUTED FURANS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097991-A1 | SUBSTITUTED FURANS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | XDH, TXN2, FABP3 | MEN1 1583/4885KMT2A 4756/4885PLA2G1B 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.